Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Prestige Brands Holdings, Inc / Equity Bottom-Up

<ul><li>Prestige Consumer Healthcare has moved into the spotlight after agreeing to acquire Breathe Right and a portfolio of adjacent over-the-counter brands from Foundation Consumer Healthcare for $1.045 billion, or about $900 million net of anticipated tax benefits.</li><li>The transaction, announced in March 2026, would add roughly $200 million of revenue and about $95 million of EBITDA based on the twelve months ended December 31, 2025, with Breathe Right accounting for about two-thirds of the portfolio’s sales and profitability.</li><li>Management has framed the deal as consistent with its long-standing playbook: buying trusted, category-leading consumer health brands with durable cash flow, strong margins, and room for brand building.</li></ul>

Prestige Consumer Healthcare has moved into the spotlight after agreeing to acquire Breathe Right and a portfolio of adjacent over-the-counter brands from Foundation Consumer Healthcare for $1.045 billion, or about $900 million net of anticipated tax benefits.The transaction, announced in March 2026, would add roughly $200 million of revenue and about $95 million of EBITDA based on the twelve months ended December 31, 2025, with Breathe Right accounting for about two-thirds of the portfolio’s sales and profitability.Management has framed the deal as consistent with its long-standing playbook: buying trusted, category-leading consumer health brands with durable cash flow, strong margins, and room for brand building.

Prestige Healthcare Is Buying Breathe Right—Here’s Why It Could Pay Off Big!